Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a ...

In a recent study published in the CDC’s Morbidity and Mortality Weekly Report, researchers analyzed the incidence of malignant mesothelioma mortality in females in the US. Occupational exposure to ...

In spring of this year, the Centers for Disease Control and Prevention (CDC) reported a 20-year rise in the number of mesothelioma deaths in women. Analyzing annual Multiple Cause of Death records ...

The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ...

Patients with mesothelioma may be getting a new second-line treatment, thanks to results from a recent immunotherapy trial. For patients with malignant pleural mesothelioma — which makes up about 90 ...

Please provide your email address to receive an email when new articles are posted on . “In clinic, we have seen some people experience durable clinical benefit from pembrolizumab, so I was not ...

Gene expression leading to alterations in the DNA caused by asbestos exposure may explain the development of Malignant Pleural Mesothelioma (MPM), a rare and aggressive cancer. By analyzing public RNA ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line ...

In a study published recently in the journal Clinical Cancer Research, researchers at Baylor College of Medicine found that treating patients who have resectable malignant pleural mesothelioma, ...

Asbestos exposure has long been considered the primary cause of mesothelioma, influencing the course of thousands of lawsuits. However, an ever-increasing body of literature supports the thesis that ...